Formulation Development
Amphista Therapeutics Unveils New Differentiated Mechanism of Action for BRD9 Degradation
Amphista’s bifunctional BRD9 degraders selectively induce BRD9 to DCAF16 proximity and serve as molecular glues, leading to strong and rapid degradation of BRD9….
TFF Pharmaceuticals & Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program Into Preclinical Testing
TFF Pharmaceuticals, Inc. recently announced the government will be advancing several next-generation medical countermeasures (MCMs) formulated with its Thin Film Freezing technology into advanced preclinical…
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study Data
Pneumagen recently presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus…
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Descartes-08 for the treatment of myasthenia gravis (MG).…
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the successful advancement of its Phase 1 trial for Decoy20, an investigational novel package of broad immune agonists for cancer…
First-In-Class Cholesterol-Lowering Treatment & its Combination With Ezetimibe Approved In Europe to Treat Hypercholesterolemia & Significantly Reduce Cardiovascular Risk
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. jointly announced the European Commission (EC) has approved the label update of both NILEMDO (bempedoic acid) and…
AGC Biologics & BioConnection Partner to Offer New End-to-End Biopharmaceutical Drug Substance & Drug Product Development & Manufacturing Offering
AGC Biologics and BioConnection recently announced a new strategic partnership. The companies are partnering to provide end-to-end biopharmaceutical development and manufacturing capabilities for drug substance…
Asymchem Secures Former Pfizer Development & API Pilot Plant Manufacturing Facilities
Asymchem Laboratories (Tianjin) Co., Ltd. recently announced today it will operate the former Pfizer UK small molecule API pilot plant and part of the development…
Alvotech & Dr. Reddy’s Enter Commercialization Collaboration
Alvotech and Dr. Reddy’s Laboratories SA recently announced the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to….
Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Lipella Pharmaceuticals Inc. recently announced the receipt of US FDA Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a…
Limula Raises $6.8M to Democratise Access to Life-Saving Cell & Gene Therapies With Swiss-Made Manufacturing Platform
Over the past decade, several breakthrough Cell and Gene Therapy products have been approved in the US and Europe to turn stem cells and immune…
Molecure Receives Approval to Initiate Phase 2 Clinical Trial for the Treatment of Pulmonary Sarcoidosis
Molecure S.A. recently announced it has received national regulatory approvals from Denmark, France, Greece, Germany, and Norway to conduct a Phase 2 clinical trial for…
Sana Biotechnology Highlights Novel In Vivo Preclinical Data Showing Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-Based Neurodegenerative Conditions
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice….
Premium Cell Culture Ingredients From Actylis
Download the Actylis Cell Culture Ingredients brochure to discover our product list or ask for a sample of a specific product…..
TFF Pharmaceuticals & Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
TFF Pharmaceuticals, Inc recently announced that, in collaboration with Cleveland Clinic, the company is advancing multiple multivalent universal influenza vaccines to protect against seasonal and…
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver From EMA for Certepetide in Pancreatic Cancer
Lisata Therapeutics, Inc. recently announced it has reached agreement with the European Medicines Agency (EMA) on a Paediatric Investigation Plan (PIP) for Lisata’s lead investigational…
Coya Therapeutics Announces $5-Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation
Coya Therapeutics, Inc. recently announces the Alzheimer’s Drug Discovery Foundation (ADDF) has purchased 603,136 shares of the company’s common stock at a purchase price of…
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program Reduces the Important Inflammatory & Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently presented positive preclinical data demonstrating its lead program GRI-0621 reduces the important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).…
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio, Inc. recently announced the first patient has been dosed in its Phase 2 TRANQUILITY trial, marking the initiation of its clinical development program…
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc. recently announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau…
